A Phase I, Open Label, Dose Escalation and Cohort Expansion Study to Evaluate the Safety and Immune Response to Autologous Dendritic Cells Transduced With Ad-GMCAIX in Patients With Metastatic Renal Cell Carcinoma
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 10 Feb 2018
At a glance
- Drugs Ad-GMCAIX transduced dendritic cells (Primary)
- Indications Renal cell carcinoma
- Focus Adverse reactions
- 10 Feb 2018 Results (n=9) presented at the 2018 Genitourinary Cancers Symposium
- 02 Jan 2018 Planned primary completion date changed from 1 Dec 2017 to 1 Dec 2018.
- 02 Jan 2018 Status changed from recruiting to active, no longer recruiting.